1. The document summarizes evidence on administering chemotherapy during pregnancy for breast cancer. Two prospective studies found that weekly regimens of epirubicin or FAC chemotherapy appeared safe for mother and neonate.
2. Data on transplacental transfer of chemotherapy in animal models found lower transfer rates for anthracyclines, paclitaxel, and docetaxel compared to cyclophosphamide and carboplatin.
3. Case reports on trastuzumab administration during pregnancy generally reported no adverse effects on the mother but increased risk of fetal complications like anhydramnios and respiratory failure.
Fertility And Pregnancy Outcome In Cancer PatientsMamdouh Sabry
Better life of Cancer patients during childhood and age reproductive period regarding fertility, fertility preservation and pregnancy outcome is the main concern.concentrating upon different safe diagnostic modalities, management and outcome.
Advance in diagnosis & treatment of cancers has led to high cure rate & longer survival.
Nearly 1 in 12 cases detected before 40 years age.
Survivors have to face infertility or early menopause.
Fertility And Pregnancy Outcome In Cancer PatientsMamdouh Sabry
Better life of Cancer patients during childhood and age reproductive period regarding fertility, fertility preservation and pregnancy outcome is the main concern.concentrating upon different safe diagnostic modalities, management and outcome.
Advance in diagnosis & treatment of cancers has led to high cure rate & longer survival.
Nearly 1 in 12 cases detected before 40 years age.
Survivors have to face infertility or early menopause.
TOPIC: “Chemical Exposures & Life-Long Reproductive Health Impacts”
We will review what we understand about reproductive biology and environmental contamination exposure. We’ll discuss the role of environmental chemicals in breast development and puberty, increased susceptibility to breast cancer and exposures during early life development of both male and female offspring and life-long impacts from chemical exposure. We’ll also discuss some of the potential health implications of energy development based on what we currently understand about exposures during early reproductive and developmental biology.
SPEAKER BIO: Suzanne Fenton, Ph.D., is Group Leader, NIH, Reproductive Endocrinology Group, Mammary Gland Development/Lactation Biology and a reproductive endocrinologist working at the National Toxicology Program Laboratory with the Division of the National Toxicology Program at National Institute of Environmental Health Sciences.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Top 10 Best Ayurvedic Kidney Stone Syrups in India
EASO2011 PanArab 1 Azim
1. BREAST CANCER DURING PREGNANCY What evidence do we have? Hatem A.Azim Jr Breast Cancer Translational Research Laboratory (BCTL) Institut Jules Bordet (IJB) Brussels, Belgium 11 th Pan Arab Cancer Congress; EASO session Casablanca; April 29 – May 1 st , 2011
2. Berry DL et al; JCO 1999 EPIDEMIOLOGY 1/3.000 pregnancies 5-10% of breast cancer < 40 y ~ 10,000 cases/year worldwide
10. Age at diagnosis 33 y (24-45) Gestational age at diagnosis W 17 (2-33) Gestation age of starting chemo W 23 (14-33) Histological grade III 82% ER –ve 70% Her-2/neu +ve 30% Number of cycles 4 (1-6) Method of delivery Vaginal 60% Cesarean 40% MD Anderson - experience
11.
12.
13.
14. Age at diagnosis 37 y (23-42) Gestation age of starting chemo W 19 (16-30) Node +ve 60% ER –ve 50% Her-2/neu +ve 20% Number of weeks 12 (4-16) Method of delivery Vaginal 40% Cesarean 60% IEO – experience
15.
16. MD Anderson (57) IEO (20) FAC Regimen Weekly epirubicin 37 W Gestational age at delivery 35 W 2/57 (4%) Pre-term pregnancies 1/20 (5%) 3/57 Congenital anomalies 1/20 Maternal outcome at 38m 70% DFS 70% 77% OS 85%
17.
18.
19. Long-term effects of in-utero exposure to doxorubicin-based regimens Aviles A et al; Ann Oncol 2006 Hahn K et al; Cancer 2006 Median FU Number Late effects Doxorubicin-based regimens (leukemia/lymphoma) 18 Y 89 None FAC (CI Doxo) 6 Y 18 None
20. Long-term effects of in-utero exposure to weekly epirubicin (n=30) Updated Peccatori F et al; Breast Ca Res Treat 2009 Normal Development !! Age 0-1 Age 2-3 Age 4-5 Age 6-7 Age 8 N° 5 10 9 3 3
23. Transplacental transfer of chemotherapy in baboon models * % during the first 25h from maternal exposure Van Calsteren V et al; Gynecol Oncol 2010 Van Calsteren V et al; Int J Gynecol Cancer 2010 Drug % in fetus * Total No. (Detected) Doxorubicin 7.5 ± 3.2 15 ( 6) Epirubicin 4.0 ± 1.6 11 (8) Paclitaxel 1.4 ± 0.8 11 (7) Docetaxel 0 9 (0) Cyclophosphamide 25.1 ± 6.3 4 (3) Carboplatin 57.5 ± 14.2 7 (7)
24.
25.
26.
27.
28. HER2 plays a pivotal role in the development of different foetal organs LUNG KIDNEY INTESTINE SKIN Patel NV et al; Am J Respirol Mol Biol 2000 Kokai Y et al; PNAS 1987
29.
30. A: adjuvant; M: metastatic; T: trastuzumab; NS: not significant; pre: preconception; EF: ejection fraction; IUGR: intrauterine growth restriction; vag blee: vaginal bleeding; PROM; premature rupture of membranes; NAD: no abnormality detected; RF: renal failure; Resp F: respiratory failure Setting Regimen Time Mother Pregnancy Baby Watson 2005 A T Pre, 1 st , 2 nd NS Anhydramnios NAD Fanale 2005 M T+ vinorelbine 3 rd NS NS NAD Waterston 2006 A T Pre NS NS NAD Bader 2007 M T + paclitaxel 2 nd NS Anhydramnios, IUGR Transient Resp F,RF Shrim 2007 M T Pre, 1 st , 2 nd EF decrease NS Transient RF Sekar 2007 M T + docetaxel 2 nd , 3 rd NS Anhydramnios NAD Witzel 2008 M T Pre, 1 st , 2 nd , 3 rd NS Anhydramnios, vag blee Resp F, died Berveiller 2008 A T Pre NS Ectopic preg., E. Aborton … Pant 2008 M T Pre, 1 st , 2 nd , 3 rd NS Anhydramnios NAD Weber 2008 M T Pre, 1 st , 2 nd NS Anhydramnios Resp F, died Warraich 2009 A T + tam + LHRH Pre, 1 st , 2 nd , 3 rd NS Anhydramnios Res. F, fetal death after 40 minutes Beale 2009 A T + tam Pre, 1 st , 2 nd NS Anhydramnios, PROM Twins: 1) RF, Resp F, Death 2) Transient Resp. F Azim Jr 2009 A T Pre NS NS NAD Goodyer 2009 M A T T 2 nd , Pre None None Premature
31. Setting Regimen Time Mother Pregnancy Baby Watson 2005 A Herceptin Pre, 1 st , 2 nd NS Anhydramnios NAD Fanale 2005 M Herceptin + vinorelbine 3 rd NS NS NAD Waterston 2006 A Herceptin Pre NS NS NAD Bader 2007 M Herceptin + paclitaxel 2 nd NS Anhydramnios, IUGR Transient Resp F,RF Shrim 2007 M Herceptin Pre, 1 st , 2 nd EF decrease NS Transient RF Sekar 2007 M Herceptin + docetaxel 2 nd , 3 rd NS Anhydramnios NAD Witzel 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios, vag blee Resp F, died Berveiller 2008 A Herceptin Pre NS Ectopic preg., E. Aborton … Pant 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios NAD Weber 2008 M Herceptin Pre, 1 st , 2 nd NS Anhydramnios Resp F, died Warraich 2009 A Herceptin + tamoxifen + gasorelin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios Res. F, fetal death after 40 minutes Beale 2009 A Herceptin + tamoxifen Pre, 1 st , 2 nd NS Anhydramnios, PROM Twins: 1) RF, Res. F, Death 2) Transient Res. F Azim Jr 2009 A Herceptin Pre NS NS NAD
32.
33. Setting Regimen Time Mother Pregnancy Baby Watson 2005 A Herceptin Pre, 1 st , 2 nd NS Anhydramnios NAD Fanale 2005 M Herceptin + vinorelbine 3 rd NS NS NAD Waterston 2006 A Herceptin Pre NS NS NAD Bader 2007 M Herceptin + paclitaxel 2 nd NS Anhydramnios, IUGR Transient Resp F,RF Shrim 2007 M Herceptin Pre, 1 st , 2 nd EF decrease NS Transient RF Sekar 2007 M Herceptin + docetaxel 2 nd , 3 rd NS Anhydramnios NAD Witzel 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios, vag blee Resp F, died Berveiller 2008 A Herceptin Pre NS Ectopic preg., E. Aborton … Pant 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios NAD Weber 2008 M Herceptin Pre, 1 st , 2 nd NS Anhydramnios Resp F, died Warraich 2009 A Herceptin + tamoxifen + gasorelin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios Res. F, fetal death after 40 minutes Beale 2009 A Herceptin + tamoxifen Pre, 1 st , 2 nd NS Anhydramnios, PROM Twins: 1) RF, Res. F, Death 2) Transient Res. F Azim Jr 2009 A Herceptin Pre NS NS NAD
34. Setting Regimen Time Mother Pregnancy Baby Watson 2005 A Herceptin Pre, 1 st , 2 nd NS Anhydramnios NAD Fanale 2005 M Herceptin + vinorelbine 3 rd NS NS NAD Waterston 2006 A Herceptin Pre NS NS NAD Bader 2007 M Herceptin + paclitaxel 2 nd NS Anhydramnios, IUGR Transient Resp F,RF Shrim 2007 M Herceptin Pre, 1 st , 2 nd EF decrease NS Transient RF Sekar 2007 M Herceptin + docetaxel 2 nd , 3 rd NS Anhydramnios NAD Witzel 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios, vag blee Resp F, died Berveiller 2008 A Herceptin Pre NS Ectopic preg., E. Aborton … Pant 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios NAD Weber 2008 M Herceptin Pre, 1 st , 2 nd NS Anhydramnios Resp F, died Warraich 2009 A Herceptin + tamoxifen + gasorelin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios Res. F, fetal death after 40 minutes Beale 2009 A Herceptin + tamoxifen Pre, 1 st , 2 nd NS Anhydramnios, PROM Twins: 1) RF, Res. F, Death 2) Transient Res. F Azim Jr 2009 A Herceptin Pre NS NS NAD
49. ABORTION DOES NOT IMPROVE PROGNOSIS Unpublished data Full-term delivery (n=24) Abortion/anticipated delivery (n=38) Log-rank p=0.03
50. INFERIOR DFS AT MEDIAN FU 4 YEARS Unpublished data Disease free survival (DFS) Overall survival (OS) Log-rank p:0.01 HR 2.3 (95% CI 1.3-4.2)* * Adjusted for T, N, age, HER2, ki67, perivascular invasion Log-rank p:0.17 HR 1.7 (95% CI 0.8-3.9)* BCP BCP Controls Controls
51.
52. Elective Systemic therapy in pregnancy Summary Consider weekly application Anthracycline-based regimen √ Taxanes 2 nd best Trastuzumab X Tamoxifen X Bisphosphonates Better postponed